Masimo Expands $500,000 Performance Guarantee to Include All Commercially Available Pulse Oximetry Technologies

February 7, 2007
Masimo guarantees its Masimo SET pulse oximetry will outperform any other commercially available technology in a hospital evaluation or it will pay up to $500,000

Irvine, California February 7, 2007 - Masimo, the inventor of Pulse CO-Oximetry and Read-Through Motion and Low Perfusion pulse oximetry, today announced that it is expanding its $500,000 performance guarantee to include all other commercially available pulse oximetry technologies. If, after a side-by-side hospital evaluation, Masimo SET does not outperform any other commercially available pulse oximetry technology under the most challenging conditions of motion and low perfusion, Masimo will pay up to $500,000 towards the purchase of that pulse oximetry. This offer is available only to hospitals whose goal is to upgrade their pulse oximetry hospital-wide. Important details, conditions and qualifications for the guarantee are available on Masimo's web page:

Masimo SET is the most accurate and reliable pulse oximetry technology in the world under conditions of motion and low perfusion, clinically proven in more than 100 independent and objective studies to provide the most trustworthy SpO2 readings even under the most difficult clinical conditions.  These studies prove Masimo SET delivers improvements in outcomes, safety and efficiency while decreasing costs. Because of this, Masimo SET is considered the "gold standard" pulse oximetry technology.

"We are hopeful that decision makers within hospitals see this guarantee as a 'can't lose' offer," stated Joe E. Kiani, Founder and CEO of Masimo. "If the evaluation proves that their level of care can be improved with Masimo SET, not only will they benefit from improved patient outcomes and safety, but in most cases, the conversion can be completed with no capital outlay and no increase in annual operating costs. If the evaluation proves that Masimo is not the best performing, the hospital will receive $500,000 towards the purchase of another technology that can deliver similar patient care benefits."

Mr. Kiani continued: "We have converted hundreds of leading hospitals, including nearly two thirds of hospitals on the U.S. News and World Reports Honor Roll. The national drive to improve patient care and safety and reduce medical errors has been a primary driver for many of these hospitals' decision to evaluate and convert to Masimo SET technology. We are grateful that our products can play a role in this noble endeavor."

About Masimo
Masimo develops innovative monitoring technologies that significantly improve patient care-helping solve "unsolvable" problems. In 1995, the company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET and with it virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent clinical studies have confirmed that Masimo SET technology allows clinicians to accurately monitor blood oxygen saturation in critical care situations-establishing the technology as the "gold standard" pulse oximetry and substantially contributing to improved patient outcomes. In 2005 Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions. Masimo, founded in 1989, has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at

Tom McCall
Masimo Corporation

Masimo, SET, Signal Extraction Technology, Radical, Radical-7, Rad57, APOD, and Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications are registered trademarks of Masimo Corp. Rainbow, SpCO, SpMet, SpHb and Pulse CO-Oximeter are trademarks of Masimo Corp.